A protein named c-Myc is causally implicated in over 50% of all human cancers. Preliminary work supports two proteins (POZ domain protein and c-Myc cofactor Miz-1) as a new drug target to disable c-Myc function. We have identified small molecules which act on this target and will now serve develop a series of optimized and […]
Read More